Skip to main content
Signal8

Biomind Labs Inc. (BMNDF)

Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression. Another key candidate, BMND08, a derivative of 5-Methoxy-N,N-dimethyltryptamine, is also in Phase II trials, addressing depression and anxiety specifically in patients experiencing cognitive decline associated with Alzheimer's disease. The company's broader development portfolio includes early-stage and preclinical candidates such as BMND02 for fibromyalgia, BMND03 for substance use disorders, BMND05 for persistent pain management, BMND06 for inflammatory conditions, and BMND07 for severe clinical depression. Biomind Labs Inc. maintains its headquarters in Canelones, Uruguay.

Sector: Biotechnology

Industry: Biotechnology

Biomind Labs Inc. logo

Biomind Labs Inc.

OTC:BMNDFHealthcare
-13.95%$0.2153
CLOSED
Mkt Cap$16.7M
EV-
Float49.41M
O/S77.57M
VOL250 sh
$ Vol$54
RVOL0.22×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Biomind Labs Inc. logoOTC:BMNDFClosed$0.2153-13.95%
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 49.41M · FMP free float

2.2K
Oct 30 (18d)prev 2.2K– 0.0%
6.05
Oct 30 (18d)prev 999.99▼ 99.4%
Borrow (IBKR)

The cost to borrow BMNDF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
100.0%
Nov 12 (5d)prev 100.0%– 0.0 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

31
Oct 1 (47d)prev 1.0K▼ 97.0%
Price, short interest & fails to deliver
Short interest · today's share basis8 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20262.2K sh
Oct 15, 20262.2K sh
Sep 30, 20262.2K sh
Sep 15, 202619.1K sh
Aug 31, 202627.6K sh
Latest fails to deliver
DateShares failed
Oct 1, 202631 sh
Sep 30, 20261.0K sh
Sep 29, 20261.0K sh
Sep 16, 2026946 sh
Sep 15, 20261.0K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 12
Latest sessions
DateReported short
Nov 12, 2026100.0%
Aug 17, 2026100.0%
Aug 12, 2026100.0%
Aug 10, 202641.2%
Aug 7, 2026100.0%
23-session median 87.5%mean 68.7%range 0.0–100.0%

130 calendar days requested; 24 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for BMNDF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 2,196 BMNDF shares were sold short (<0.01% of a 49.41M-share float, 6.05 days to cover).